By: Kelly Grant
New report finds that Trikafta patients’ admissions to hospital fell by an average of 65 per cent over one year – but at a list price of over $300,000, the drug is not yet considered cost effective
Kelly Grant is a health news reporter at The Globe and Mail. She covers a wide range of topics related to medicine and healthcare, including medical specialties, health and wellness, and the healthcare system, while also touching on themes such as education and alternative medicine. Kelly's work has been featured in various outlets including Castanet Media, The Irish News, and the San Francisco Chronicle.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Canada (National)
Not enough data
Kelly Grant's coverage predominantly focuses on healthcare, nursing, medical research, public health, and healthcare policy in Canada. She often cites data and government announcements to support her reporting. To effectively reach out to her, consider providing insights or expertise related to Canadian healthcare policies, public health initiatives, healthcare data analysis or scientific research within the Canadian context.
Given Kelly's focus on citing data and government announcements in her articles, experts who can provide statistical analysis or insights into governmental policies concerning healthcare in Canada would likely be well-received by her for potential interviews or contributions to her pieces.
This information evolves through artificial intelligence and human feedback. Improve this profile .